M.J. Méndez Vidal

849 total citations
25 papers, 166 citations indexed

About

M.J. Méndez Vidal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M.J. Méndez Vidal has authored 25 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M.J. Méndez Vidal's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). M.J. Méndez Vidal is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). M.J. Méndez Vidal collaborates with scholars based in Spain, Italy and United States. M.J. Méndez Vidal's co-authors include Juan de la Haba-Rodríguez, Enrique Aranda, M.J. Rubio Pérez, Teresa Alonso Gordoa, Núria Torner, Javier Puente, Núria Soldevila, Jesús García-Donás, Daniel Castellano and María Ángeles Marcos and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

M.J. Méndez Vidal

25 papers receiving 160 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.J. Méndez Vidal Spain 7 76 58 47 42 40 25 166
Ryoichi Honda Japan 8 50 0.7× 82 1.4× 23 0.5× 14 0.3× 29 0.7× 26 183
Marga Lang-Welzenbach Germany 5 28 0.4× 125 2.2× 36 0.8× 22 0.5× 22 0.6× 9 207
Michael Bint Australia 7 134 1.8× 68 1.2× 19 0.4× 75 1.8× 18 0.5× 10 242
Shôichi Ihara Japan 8 69 0.9× 63 1.1× 28 0.6× 15 0.4× 26 0.7× 20 148
Haiwei Du China 10 97 1.3× 94 1.6× 27 0.6× 44 1.0× 31 0.8× 30 262
Rossa Wai Kwun Chiu Hong Kong 5 69 0.9× 15 0.3× 40 0.9× 49 1.2× 42 1.1× 6 266
Naoyuki Hasegawa Japan 9 60 0.8× 71 1.2× 75 1.6× 14 0.3× 20 0.5× 38 278
Melissa Pavilack United States 13 247 3.3× 158 2.7× 91 1.9× 47 1.1× 18 0.5× 26 330
Hamadi Almotlak France 8 75 1.0× 78 1.3× 12 0.3× 15 0.4× 17 0.4× 19 134
Carlos Aguado Spain 9 115 1.5× 174 3.0× 25 0.5× 17 0.4× 13 0.3× 41 241

Countries citing papers authored by M.J. Méndez Vidal

Since Specialization
Citations

This map shows the geographic impact of M.J. Méndez Vidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.J. Méndez Vidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.J. Méndez Vidal more than expected).

Fields of papers citing papers by M.J. Méndez Vidal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.J. Méndez Vidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.J. Méndez Vidal. The network helps show where M.J. Méndez Vidal may publish in the future.

Co-authorship network of co-authors of M.J. Méndez Vidal

This figure shows the co-authorship network connecting the top 25 collaborators of M.J. Méndez Vidal. A scholar is included among the top collaborators of M.J. Méndez Vidal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.J. Méndez Vidal. M.J. Méndez Vidal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Juan-Fita, María José, Urbano Anido Herranz, M.J. Méndez Vidal, et al.. (2023). Phase II trial evaluating olaparib maintenance in patients with metastatic castration resistant prostate cancer (mCRPC) after docetaxel treatment, reaching partial or stable response: SOGUG-IMANOL study.. Journal of Clinical Oncology. 41(6_suppl). 168–168. 2 indexed citations
3.
Porta, V. Guillem, Carlos Camps, Miguel Á. Climent Durán, et al.. (2021). Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain. Clinical & Translational Oncology. 24(3). 495–502. 1 indexed citations
4.
Carles, Joan, Teresa Alonso, B. Mellado González, et al.. (2020). 639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide. Annals of Oncology. 31. S525–S526. 1 indexed citations
5.
Sartor, Oliver, Daniel Heinrich, Neil Mariados, et al.. (2019). Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases. The Prostate. 79(14). 1683–1691. 16 indexed citations
6.
Arija, Jóse Ángel Arranz, Begoña P. Valderrama, Teresa Alonso Gordoa, et al.. (2019). PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer. Annals of Oncology. 30. v352–v353. 3 indexed citations
7.
Cattrini, Carlo, Nuria Romero-Laorden, Elena Castro, et al.. (2019). Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study. Annals of Oncology. 30. v345–v346. 2 indexed citations
8.
Jané, Mireia, M.J. Méndez Vidal, Núria Soldevila, et al.. (2019). Epidemiological and clinical characteristics of children hospitalized due to influenza A and B in the south of Europe, 2010–2016. Scientific Reports. 9(1). 12853–12853. 19 indexed citations
9.
Juan-Fita, María José, Begoña Mellado, M.J. Méndez Vidal, et al.. (2018). Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response. Annals of Oncology. 29. viii301–viii301. 1 indexed citations
10.
Jané, Mireia, M.J. Méndez Vidal, Neus Camps, et al.. (2018). A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015. Eurosurveillance. 23(13). 10 indexed citations
11.
Romero-Laorden, Nuria, J.M. Piulats Rodriguez, Ángela del Pozo, et al.. (2017). PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 28. v619–v619. 6 indexed citations
12.
13.
Sartor, Oliver, Daniel Heinrich, Neil Mariados, et al.. (2016). Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases. Annals of Oncology. 27. vi255–vi255. 1 indexed citations
14.
Keizman, Daniel, Luke T. Nordquist, Neil Mariados, et al.. (2016). 764 Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC). European Urology Supplements. 15(3). e764–e764a. 1 indexed citations
15.
León‐Mateos, Luis, Cristina Suárez, Antonia Arjonilla, et al.. (2013). Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Targeted Oncology. 9(1). 9–24. 5 indexed citations
16.
García-Donás, Jesús, Marta Guix, Miguel Á. Climent Durán, et al.. (2013). Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.. Journal of Clinical Oncology. 31(15_suppl). 4587–4587. 4 indexed citations
17.
Haba-Rodríguez, Juan de la, et al.. (2005). Breast cancer screening: another point of view. European Journal of Cancer Prevention. 14(1). 1–5. 2 indexed citations
18.
Vidal, M.J. Méndez, et al.. (2005). Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clinical & Translational Oncology. 7(6). 258–261. 33 indexed citations
19.
Haba-Rodríguez, Juan de la, et al.. (2004). Reactivación del virus de la hepatitis Ben paciente oncológico tras tratamiento con quimioterapia: hepatitis fulminante. 6(1). 48–50. 1 indexed citations
20.
Haba-Rodríguez, Juan de la, et al.. (2003). Adjuvant Treatment in Elderly Patients With Breast Cancer. American Journal of Clinical Oncology. 26(4). 398–401. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryoichi Honda Breakdown of academic impact, for papers by Marga Lang-Welzenbach Breakdown of academic impact, for papers by Michael Bint Breakdown of academic impact, for papers by Shôichi Ihara Breakdown of academic impact, for papers by Haiwei Du Breakdown of academic impact, for papers by Rossa Wai Kwun Chiu Breakdown of academic impact, for papers by Naoyuki Hasegawa Breakdown of academic impact, for papers by Melissa Pavilack Breakdown of academic impact, for papers by Hamadi Almotlak Breakdown of academic impact, for papers by Carlos Aguado
Rankless by CCL
2026